HARMONi-6 Results: Ivonescimab’s 34% Survival Benefit Redefines First-Line Squamous NSCLC | Answer

HARMONi-6 Results: Ivonescimab’s 34% Survival Benefit Redefines First-Line Squamous NSCLC | Answer | Studio Global